Novartis India Limited
NSE:NOVARTIND.NS
674 (INR) • At close October 25, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 3,350.7 | 3,787.4 | 3,875.7 | 3,656.1 | 4,113.5 | 4,503.4 | 5,171.8 | 6,562.2 | 8,083.2 | 8,733.8 | 8,622.3 | 9,033.6 | 8,442.9 | 7,086.426 | 6,241.03 | 5,994.802 | 5,534.476 |
| Cost of Revenue
| 2,254.1 | 2,016.9 | 1,814.7 | 1,496.3 | 1,853.6 | 2,021.1 | 2,497.6 | 3,114.4 | 3,496.6 | 3,529.1 | 3,930.7 | 3,716.5 | 3,144.9 | 2,734.961 | 2,512.705 | 2,524.155 | 2,455.746 |
| Gross Profit
| 1,096.6 | 1,770.5 | 2,061 | 2,159.8 | 2,259.9 | 2,482.3 | 2,674.2 | 3,447.8 | 4,586.6 | 5,204.7 | 4,691.6 | 5,317.1 | 5,298 | 4,351.465 | 3,728.325 | 3,470.647 | 3,078.73 |
| Gross Profit Ratio
| 0.327 | 0.467 | 0.532 | 0.591 | 0.549 | 0.551 | 0.517 | 0.525 | 0.567 | 0.596 | 0.544 | 0.589 | 0.628 | 0.614 | 0.597 | 0.579 | 0.556 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 64.2 | 67.8 | 54.6 | 72 | 89.1 | 71.1 | 78.8 | 89.9 | 0 | 0 | 0 | 397.9 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 279.8 | 356.6 | 397.7 | 539.9 | 602.9 | 724.8 | 729.6 | 451.5 | 0 | 0 | 0 | 931.5 | 0 | 0 | 0 | 0 |
| SG&A
| 470.1 | 344 | 424.4 | 452.3 | 611.9 | 692 | 795.9 | 808.4 | 541.4 | 0 | 0 | 0 | 1,329.4 | 0 | 0 | 0 | 0 |
| Other Expenses
| 616.8 | 581.1 | 63.8 | 40.4 | 1.9 | 0.1 | 31.1 | 62.9 | 48.8 | 71.6 | 66.4 | 59.3 | 22.4 | 2,163.292 | 1,939.053 | 1,827.988 | 1,627.019 |
| Operating Expenses
| 470.1 | 1,176.6 | 1,869 | 2,011 | 2,251.3 | 2,351.3 | 2,739.9 | 3,224.8 | 4,185.4 | 5,241.6 | 4,668.9 | 4,425.7 | 3,521.1 | 2,163.292 | 1,939.053 | 1,827.988 | 1,627.019 |
| Operating Income
| 626.5 | 600.8 | 237.7 | 168.7 | 8.4 | 131 | -65.7 | 223 | 401.2 | -36.9 | 22.7 | 891.4 | 1,776.9 | 2,188.173 | 1,789.272 | 1,642.659 | 1,451.711 |
| Operating Income Ratio
| 0.187 | 0.159 | 0.061 | 0.046 | 0.002 | 0.029 | -0.013 | 0.034 | 0.05 | -0.004 | 0.003 | 0.099 | 0.21 | 0.309 | 0.287 | 0.274 | 0.262 |
| Total Other Income Expenses Net
| 601.9 | 553 | -275.9 | 231.7 | 278 | 726.7 | 1,640.9 | 694.3 | 2,413.5 | 955.5 | 876.3 | 802.8 | 470 | 0.944 | 8.733 | 86.459 | 91.427 |
| Income Before Tax
| 1,228.4 | 1,153.8 | -38.2 | 400.4 | 286.4 | 857.7 | 1,575.2 | 917.3 | 2,814.7 | 918.6 | 899 | 1,694.2 | 2,246.9 | 2,189.117 | 1,798.005 | 1,729.118 | 1,543.138 |
| Income Before Tax Ratio
| 0.367 | 0.305 | -0.01 | 0.11 | 0.07 | 0.19 | 0.305 | 0.14 | 0.348 | 0.105 | 0.104 | 0.188 | 0.266 | 0.309 | 0.288 | 0.288 | 0.279 |
| Income Tax Expense
| 376.5 | 120.2 | -1 | 191.4 | 185.6 | 340 | 791.6 | 345.1 | 767.6 | 125.3 | -86.3 | 496.9 | 726.7 | 722.391 | 638.113 | 692.021 | 570.792 |
| Net Income
| 851.9 | 1,033.6 | -37.2 | 209 | 100.8 | 517.7 | 783.6 | 572.2 | 1,986.1 | 791.1 | 985.3 | 1,197.3 | 1,520.2 | 1,466.726 | 1,159.892 | 1,037.097 | 972.346 |
| Net Income Ratio
| 0.254 | 0.273 | -0.01 | 0.057 | 0.025 | 0.115 | 0.152 | 0.087 | 0.246 | 0.091 | 0.114 | 0.133 | 0.18 | 0.207 | 0.186 | 0.173 | 0.176 |
| EPS
| 34.5 | 41.86 | -1.51 | 8.46 | 4.08 | 20.97 | 28.43 | 19.1 | 0.62 | 24.75 | 30.83 | 37.46 | 47.56 | 45.89 | 36.29 | 32.45 | 30.42 |
| EPS Diluted
| 34.5 | 41.86 | -1.51 | 8.46 | 4.08 | 20.97 | 28.43 | 19.1 | 0.62 | 24.75 | 30.83 | 37.46 | 47.56 | 45.89 | 36.29 | 32.45 | 30.42 |
| EBITDA
| 652.6 | 1,235.6 | 566 | 553.9 | 482.1 | 597.7 | 1,456.8 | 959.6 | -1,216.8 | 856.9 | 58.8 | 927.3 | 2,302.8 | 2,211.996 | 1,811.785 | 1,669.543 | 1,480.214 |
| EBITDA Ratio
| 0.195 | 0.326 | 0.146 | 0.152 | 0.117 | 0.133 | 0.282 | 0.146 | -0.151 | 0.098 | 0.007 | 0.103 | 0.273 | 0.312 | 0.29 | 0.278 | 0.267 |